Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3885429 | 0.78 | NPC1 (0.37) | NPC1RAB9A | |
| SCHEMBL419727 | 0.77 | ESR2 (0.37) | ESR1ESR2EPHX1EPHX2 | |
| SCHEMBL422791 | 0.74 | ESR1 (0.45) | ESR1ESR2KDM1AEPHX1EPHX2 | |
| SCHEMBL424505 | 0.73 | EPHX1 (0.45) | ESR1ESR2KDM1AEPHX1EPHX2 | |
| SCHEMBL25026044 | 0.72 | ESR1 (0.44) | ESR1ESR2KDM1AEPHX1EPHX2 | |
| SCHEMBL1470211 | 0.72 | EPHX1 (0.42) | ESR1ESR2KDM1AEPHX1EPHX2 | |
| SCHEMBL8164423 | 0.72 | — | — | |
| Ethylene SCHEMBL8379309 | 0.71 | ESR1 (0.42) | ESR1ESR2KDM1AEPHX1EPHX2 | |
| SCHEMBL2948300 | 0.70 | USP2 (0.49) | ESR2EPHX1 | |
| SCHEMBL8325073 | 0.70 | CYP3A4 (0.37) | NPC1RAB9AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895551-B2 | Acrylamide compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| EP-2414332-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
| WO-2010114181-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | NPC1 3355/4885RAB9A 3837/4885ESR1 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.